You signed in with another tab or window. Reload to refresh your session.You signed out in another tab or window. Reload to refresh your session.You switched accounts on another tab or window. Reload to refresh your session.Dismiss alert
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
@@ -221,7 +221,7 @@ Note that the WHO will generally be unable to make statements that their more pr
## Therapeutics and vaccines
*[Cytel's Global Coronavirus COVID-19 Clinical Trial Tracker](https://www.covid-trials.org/)
*[Coronavirus Vaccine Update, July 7](https://blogs.sciencemag.org/pipeline/archives/2020/06/29/coronavirus-vaccine-update-june-29) by Derek Lowe nicely covers the "frontrunners" and also some lesser known vaccines, divided by type, with commentary
*[Coronavirus Vaccine Update, July 7](https://blogs.sciencemag.org/pipeline/archives/2020/06/29/coronavirus-vaccine-update-june-29) by Derek Lowe nicely covers the "frontrunners" and also some lesser known vaccines, divided by type, with commentary; [Coronavirus Vaccine Roundup, Early September](https://blogs.sciencemag.org/pipeline/archives/2020/09/03/coronavirus-vaccine-roundup-early-september) follows up on that
*[The race for coronavirus vaccines: a graphical guide](https://www.nature.com/articles/d41586-020-01221-y), an introductory article on Nature
*[Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext), encouraging preliminary results from the "Oxford" vaccines, showing an acceptable safety profile and strong immune response after a booster, while [Derek Lowe's "In The Pipeline" blog provides a critical commentary](https://blogs.sciencemag.org/pipeline/archives/2020/07/20/new-data-on-the-oxford-az-vaccine) on it
*[Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20\)31208-3/fulltext), published on The Lancet, concludes after testing an experimental vaccine on about 200 individual that, despite some mild or moderate adverse effect, this vaccine may be safe and at least temporarily immunogenic in all individuals who received it
